The use of cholesterol-lowering reagents or other cholesterol-depleting reagents has been found to improve the TβRII/TβRI binding ratio and enhance TGF-β responsiveness, thereby promoting EMT in breast cancer [39]. This evidence concerns the gene TGFBR2 and breast cancer.